JP2025509680A5 - - Google Patents

Info

Publication number
JP2025509680A5
JP2025509680A5 JP2024555003A JP2024555003A JP2025509680A5 JP 2025509680 A5 JP2025509680 A5 JP 2025509680A5 JP 2024555003 A JP2024555003 A JP 2024555003A JP 2024555003 A JP2024555003 A JP 2024555003A JP 2025509680 A5 JP2025509680 A5 JP 2025509680A5
Authority
JP
Japan
Prior art keywords
weight
approximately
pharmaceutical composition
composition according
kinase inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024555003A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025509680A (ja
Filing date
Publication date
Priority claimed from PCT/EP2022/058180 external-priority patent/WO2022207580A2/en
Application filed filed Critical
Priority claimed from PCT/EP2023/056506 external-priority patent/WO2023174948A2/en
Publication of JP2025509680A publication Critical patent/JP2025509680A/ja
Publication of JP2025509680A5 publication Critical patent/JP2025509680A5/ja
Pending legal-status Critical Current

Links

JP2024555003A 2022-03-14 2023-03-14 治療薬のバイオアベイラビリティを改善した組成物およびその使用 Pending JP2025509680A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263269330P 2022-03-14 2022-03-14
US63/269,330 2022-03-14
PCT/EP2022/058180 WO2022207580A2 (en) 2021-03-27 2022-03-28 Compositions having improved bioavailability of therapeutics
EPPCT/EP2022/058180 2022-03-28
PCT/EP2023/056506 WO2023174948A2 (en) 2022-03-14 2023-03-14 Compositions having improved bioavailability of therapeutics and uses thereof

Publications (2)

Publication Number Publication Date
JP2025509680A JP2025509680A (ja) 2025-04-11
JP2025509680A5 true JP2025509680A5 (cg-RX-API-DMAC10.html) 2026-03-24

Family

ID=85571360

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024555003A Pending JP2025509680A (ja) 2022-03-14 2023-03-14 治療薬のバイオアベイラビリティを改善した組成物およびその使用

Country Status (7)

Country Link
EP (1) EP4493151A2 (cg-RX-API-DMAC10.html)
JP (1) JP2025509680A (cg-RX-API-DMAC10.html)
AU (1) AU2023233811A1 (cg-RX-API-DMAC10.html)
CA (1) CA3245873A1 (cg-RX-API-DMAC10.html)
IL (1) IL315617A (cg-RX-API-DMAC10.html)
WO (1) WO2023174948A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA202407659B (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4784247A1 (en) * 2023-09-28 2026-08-05 The Regents Of The University Of California Methods and compositions of treating age-related conditions
WO2025093572A1 (en) * 2023-10-29 2025-05-08 TRx Biosciences Limited Solid dispersion compositions and uses thereof
WO2026053168A1 (en) * 2024-09-06 2026-03-12 Graviton Bioscience Bv Amorphous forms of a rock2 inhibitor and formulations thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5082667A (en) * 1988-06-07 1992-01-21 Abbott Laboratories Solid pharmaceutical dosage in tablet triturate form and method of producing same
US5885486A (en) * 1993-03-05 1999-03-23 Pharmaciaand Upjohn Ab Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof
US20020028813A1 (en) * 1997-09-03 2002-03-07 Paul F. Jackson Thioalkyl compounds, methods, and compositions for inhibiting parp activity
US6063768A (en) 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
US20060138059A1 (en) 2004-12-28 2006-06-29 Vair Larry L Jr Corona-treated polypropylene liquid filtration media
JP5758630B2 (ja) * 2007-11-15 2015-08-05 エンメエッセディ・イタリア・エッセ・エッレ・エッレ Parp阻害剤としてのピリダジノン誘導体
EP2346495B2 (en) * 2008-10-07 2023-05-24 Kudos Pharmaceuticals Limited Pharmaceutical formulation 514
CN102307576A (zh) * 2008-12-15 2012-01-04 班纳制药公司 用于增强水不溶性活性剂的释放和吸收的方法
CN101507707B (zh) * 2009-04-08 2011-01-19 邓菊娟 一种盐酸法舒地尔脂微球制剂及其制备方法
CN101926757B (zh) * 2010-09-01 2013-01-02 北京大学 一种难溶性药物的液体组合物及其制备方法
CN102813639B (zh) * 2011-06-08 2014-04-30 中国疾病预防控制中心寄生虫病预防控制所 甲苯达唑软胶囊剂
US9073944B2 (en) * 2012-02-21 2015-07-07 Merck Patent Gmbh Cyclic diaminopyrimidine derivatives
AU2014360537B2 (en) * 2013-12-04 2017-09-07 Gilead Sciences, Inc. Methods for treating cancers
ES2975417T3 (es) * 2017-03-03 2024-07-05 Inspirna Inc Formulaciones con estabilidad mejorada
WO2020079706A1 (en) * 2018-10-15 2020-04-23 Cipla Limited Pharmaceutical formulation
WO2020217235A1 (en) * 2019-04-24 2020-10-29 Aizant Drug Research Solutions Private Limited Solid dosage form of dasatinib
CN113546045B (zh) * 2021-08-18 2022-11-11 浙江大学 恢复肿瘤微环境失活树突状细胞功能的纳米制剂及应用

Similar Documents

Publication Publication Date Title
JP2024511208A5 (cg-RX-API-DMAC10.html)
JP6474732B2 (ja) 激痛治療用組成物と方法
US10857114B2 (en) Compositions and methods for treating severe pain
US20140107206A1 (en) Omega-3 pentaenoic acid compositions and methods of use
ES2200182T3 (es) Procedimiento de fabricacion de una mezcla de esteres.
US9737500B2 (en) Compositions and methods for treating severe pain
JP2009108076A (ja) リパーゼ阻害剤とショ糖脂肪酸エステルとを含む医薬組成物
JPH0714873B2 (ja) 局所性製薬組成物
JP2003509357A (ja) リパーゼ阻害剤を含有する分散処方物
USRE47316E1 (en) Oral formulations of ospemifene
WO2014158256A1 (en) Omega-3 pentaenoic acid compositions and methods of use
CN115364052B (zh) 具有高载药量的中链甘油三酯的药物组合物及其相关方法
CN106256345A (zh) 维生素c传递系统及其脂质体组合物
KR100533460B1 (ko) 난용성 약물의 가용화용 점막흡착성 조성물, 이를 이용한난용성 약물의 가용화용 제형 및 이들의 제조 방법
CN104411295B (zh) 敏感化组合物和使用方法
RU2582278C2 (ru) Трансдермальное средство для лечения и профилактики болезней суставов и мягких тканей, способ его получения и комбинированный трансдермальный препарат для лечения и профилактики болезней суставов и мягких тканей
JP3324264B2 (ja) 鼻洗浄剤
CN110461325A (zh) 包括口服或胃部施用依达拉奉的治疗
BRPI0618510A2 (pt) formulação medicamentosa lìquida ou semi-sólida
US11730709B2 (en) Compositions and methods for treating severe pain
WO1985004804A1 (fr) Agent cholagogique/cholelithotriptique
KR100524700B1 (ko) 자가미세유화형 약물전달시스템을 이용한 고지혈증치료용약제 조성물
JP2006076958A (ja) ネフローゼ症候群治療剤
KR100958892B1 (ko) 대변 연화제 및 계면활성제를 함유하는 예비농축액
Holub EPA/DHA